Metastatic Melanoma Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Melanoma pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Melanoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Metastatic Melanoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Melanoma Market.

The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Metastatic Melanoma Pipeline Report: https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Metastatic Melanoma treatment therapies with a considerable amount of success over the years.
• Metastatic Melanoma companies working in the treatment market are Immatics Biotechnologies, Replimune and Bristol Myers Squibb, Philogen, TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others, are developing therapies for the Metastatic Melanoma treatment
• Emerging Metastatic Melanoma therapies in the different phases of clinical trials are- IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, Nidlegy, TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others are expected to have a significant impact on the Metastatic Melanoma market in the coming years.
• In May 2025, Immatics announced the presentation of updated data from its ongoing Phase Ib trial assessing IMA203 in heavily pretreated metastatic melanoma patients. The company also shared information from a trial-in-progress poster on SUPRAME, the Phase III study evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have previously received checkpoint inhibitor therapy, at ASCO 2025.
• In April 2024, Obsidian Therapeutics shared an update on its Phase I first-in-human trial of OBX-115 tumor-infiltrating lymphocyte (TIL) cell therapy for advanced or metastatic melanoma. The update, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, included 25-week median follow-up safety data and newly detailed efficacy findings.
• In April 2024, Iovance Biotherapeutics revealed that clinical data on lifileucel combined with pembrolizumab for frontline advanced melanoma, along with translational findings, will be featured at the 2024 ASCO Annual Meeting.
• In December 2023, Obsidian Therapeutics reported positive top-line results from its ongoing Phase 1 first-in-human trial assessing the safety and efficacy of OBX-115, its lead-engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced or metastatic melanoma following anti-PD1 therapy.

Metastatic Melanoma Overview
Metastatic Melanoma is an advanced stage of melanoma, a type of skin cancer, where cancer cells spread beyond the original tumor site to distant organs such as the lungs, liver, brain, or bones. It occurs when melanoma cells invade the bloodstream or lymphatic system, leading to secondary tumors. Metastatic melanoma is highly aggressive but can be treated with targeted therapies (BRAF and MEK inhibitors), immunotherapy (checkpoint inhibitors like nivolumab and pembrolizumab), chemotherapy, or radiation therapy. Early detection and advanced treatments have improved survival rates and patient outcomes.

Get a Free Sample PDF Report to know more about Metastatic Melanoma Pipeline Therapeutic Assessment:
https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Metastatic Melanoma Drugs Under Different Phases of Clinical Development Include:
• IMA203: Immatics Biotechnologies
• RP1 (vusolimogene oderparepvec) plus nivolumab: Replimune and Bristol Myers Squibb
• Nidlegy: Philogen
• TILT 123: TILT Biotherapeutics
• AV-MEL-1: AiVita Biomedical
• IMM-1-104: Immuneering Corporation
• UV1: Ultimovacs ASA
• APX005: MPyxis Oncology
• EVX 01: Evaxion Biotech
• HBI-8000: HUYABIO International, LLC.
• IO102-IO103: IO Biotech
• Fianlimab: Regeneron Pharmaceuticals

Metastatic Melanoma Route of Administration
Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Metastatic Melanoma Molecule Type
Metastatic Melanoma Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Metastatic Melanoma Pipeline Therapeutics Assessment
• Metastatic Melanoma Assessment by Product Type
• Metastatic Melanoma By Stage and Product Type
• Metastatic Melanoma Assessment by Route of Administration
• Metastatic Melanoma By Stage and Route of Administration
• Metastatic Melanoma Assessment by Molecule Type
• Metastatic Melanoma by Stage and Molecule Type

DelveInsight's Metastatic Melanoma Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Metastatic Melanoma product details are provided in the report. Download the Metastatic Melanoma pipeline report to learn more about the emerging Metastatic Melanoma therapies
https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Metastatic Melanoma Therapeutics Market include:
Key companies developing therapies for Metastatic Melanoma are - Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, Taizhou Hanzhong biomedical co. LTD, Scancell Ltd, BioMed Valley Discoveries, Inc., Nykode Therapeutics, Sapience Therapeutics, BeiGene, Immunocore, Achilles Therapeutics UK Limited, Vanquish Oncology, Syntrix Biosystems, Inc., TILT Biotherapeutics, PrimeVax Immuno-Oncology Inc., Celldex Therapeutics, Taiga Biotechnologies, Inc., Galectin Therapeutics Inc, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., Miltenyi Biomedicine GmbH, CytomX Therapeutics, Inc., Seagen Inc., Immutep, Regeneron pharmaceuticals, Adaptimmune, IDEAYA Biosciences, PokeAcell, Ultimovacs ASA, Verastem, Inc., PACT Pharma, Actuate Therapeutics, Inc., and others.

Metastatic Melanoma Pipeline Analysis:
The Metastatic Melanoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.
• Metastatic Melanoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Melanoma drugs and therapies
https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Melanoma Pipeline Market Drivers
• Improving Healthcare Infrastructure, emergence of effective immune therapies are some of the important factors that are fueling the Metastatic Melanoma Market.

Metastatic Melanoma Pipeline Market Barriers
• However, lack Of Cost-Effective Treatment, side effects associated with the treatment and other factors are creating obstacles in the Metastatic Melanoma Market growth.

Scope of Metastatic Melanoma Pipeline Drug Insight
• Coverage: Global
• Key Metastatic Melanoma Companies: Immatics Biotechnologies, Replimune and Bristol Myers Squibb, Philogen, TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others
• Key Metastatic Melanoma Therapies: IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, Nidlegy, TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others
• Metastatic Melanoma Therapeutic Assessment: Metastatic Melanoma current marketed and Metastatic Melanoma emerging therapies
• Metastatic Melanoma Market Dynamics: Metastatic Melanoma market drivers and Metastatic Melanoma market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.